title: New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer.
abstract: A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly. Conventional cellular therapies, such as tumor infiltrating lymphocytes (TIL), are becoming more effective and more available. Gene therapy is becoming an important tool in adoptive cell therapy. Lymphocytes are being engineered to express high affinity T cell receptors (TCRs), chimeric antibody-T cell receptors (CARs) and cytokines. T cell subsets with more naïve and stem cell-like characteristics have been shown in pre-clinical models to be more effective than unselected populations and it is now possible to reprogram T cells and to produce T cells with stem cell characteristics. In the future, combinations of adoptive transfer of T cells and specific vaccination against the cognate antigen can be envisaged to further enhance the effectiveness of these therapies.
authors.affiliation: Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, USA. dstroncek@cc.nih.gov
authors.forename: David F
authors.initials: DF
authors.lastname: Stroncek
authors.forename: Carolina
authors.initials: C
authors.lastname: Berger
authors.forename: Martin A
authors.initials: MA
authors.lastname: Cheever
authors.forename: Richard W
authors.initials: RW
authors.lastname: Childs
authors.forename: Mark E
authors.initials: ME
authors.lastname: Dudley
authors.forename: Peter
authors.initials: P
authors.lastname: Flynn
authors.forename: Luca
authors.initials: L
authors.lastname: Gattinoni
authors.forename: James R
authors.initials: JR
authors.lastname: Heath
authors.forename: Michael
authors.initials: M
authors.lastname: Kalos
authors.forename: Francesco M
authors.initials: FM
authors.lastname: Marincola
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Miller
authors.forename: Gustavo
authors.initials: G
authors.lastname: Mostoslavsky
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Powell
authors.forename: Mahendra
authors.initials: M
authors.lastname: Rao
authors.forename: Nicholas P
authors.initials: NP
authors.lastname: Restifo
authors.forename: Steven A
authors.initials: SA
authors.lastname: Rosenberg
authors.forename: John
authors.initials: J
authors.lastname: O'Shea
authors.forename: Cornelis J M
authors.initials: CJ
authors.lastname: Melief
mesh_terms: D017690:Cell Transplantation / Q000379:methods / Q000706:statistics & numerical data / Q000639:trends*; D006801:Humans; D016219:Immunotherapy, Adoptive; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D008545:Melanoma / Q000628:therapy; D009369:Neoplasms / Q000628:therapy*